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Abstract
AIM: To study whether the severity of liver fibrosis es-
timated by the nonalcoholic fatty liver disease (NAFLD) 
fibrosis score can predict all-cause mortality, cardiac 
complications, and/or liver complications of patients 
with NAFLD over long-term follow-up. 
METHODS: A cohort of well-characterized patients 
with NAFLD diagnosed during the period of 1980-2000 
was identified through the Rochester Epidemiology 
Project. The NAFLD fibrosis score (NFS) was used to 
separate NAFLD patients with and without advanced 
liver fibrosis. We used the NFS score to classify the 
probability of fibrosis as < -1.5 for low probability, > 
-1.5 to < 0.67 for intermediate probability, and > 0.67 
for high probability. Primary endpoints included all-
cause death and cardiovascular- and/or liver-related 
mortality. From the 479 patients with NAFLD assessed, 
302 patients (63%) greater than 18 years old were in-
cluded. All patients were followed, and medical charts 
were reviewed until August 31, 2009 or the date when 
the first primary endpoint occurred. By using a stan-
dardized case record form, we recorded a detailed his-
tory and physical examination and the use of statins 
and metformin during the follow-up period.
RESULTS: A total of 302/479 (63%) NAFLD patients 
(mean age: 47 ± 13 year) were included with a follow-
up period of 12.0 ± 3.9 year. A low probability of ad-
vanced fibrosis (NFS < -1.5 at baseline) was found 
in 181 patients (60%), while an intermediate or high 
probability of advanced fibrosis (NSF > -1.5) was found 
in 121 patients (40%). At the end of the follow-up pe-
riod, 55 patients (18%) developed primary endpoints. 
A total of 39 patients (13%) died during the follow-up. 
The leading causes of death were non-hepatic ma-
lignancy (n  = 13/39; 33.3%), coronary heart disease 
(CHD) (n  = 8/39; 20.5%), and liver-related mortality (n  
= 5/39; 12.8%). Thirty patients had new-onset CHD, 
whereas 8 of 30 patients (27%) died from CHD-related 
causes during the follow-up. In a multivariate analysis, 
a higher NFS at baseline and the presence of new-on-
set CHD were significantly predictive of death (OR = 2.6 
and 9.2, respectively; P  < 0.0001). Our study showed 
a significant, graded relationship between the NFS, as 
classified into 3 subgroups (low, intermediate and high 
probability of liver fibrosis), and the occurrence of pri-
mary endpoints. The use of metformin or simvastatin 
for at least 3 mo during the follow-up was associated 
with fewer deaths in patients with NAFLD (OR = 0.2 
and 0.03, respectively; P  < 0.05). Additionally, the rate 
of annual NFS change in patients with an intermediate 
or high probability of advanced liver fibrosis was signifi-
cantly lower than those patients with a low probability 
of advanced liver fibrosis (0.06 vs  0.09, P  = 0.004). 
The annual NFS change in patients who died was sig-
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nificantly higher than those in patients who survived 
(0.14 vs  0.07, P  = 0.03). At the end of the follow-up, 
we classified the patients into 3 subgroups according to 
the progression pattern of liver fibrosis by comparing 
the NFS at baseline to the NFS at the end of the follow-
up period. Most patients were in the stable-fibrosis 
(60%) and progressive-fibrosis (37%) groups, whereas 
only 3% were in the regressive fibrosis. 
CONCLUSION: A higher NAFLD fibrosis score at base-
line and a new onset of CHD were significantly predic-
tive of death in patients with NAFLD.
© 2013 Baishideng. All rights reserved.
Key words: Nonalcoholic fatty liver disease fibrosis 
score; Prognostic predictor; Mortality; Liver complica-
tions 
Treeprasertsuk S, Björnsson E, Enders F, Suwanwalaikorn S, 
Lindor KD. NAFLD fibrosis score: A prognostic predictor for 
mortality and liver complications among NAFLD patients. World 
J Gastroenterol 2013; 19(8): 1219-1229  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v19/i8/1219.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v19.i8.1219
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is one of  the 
most common causes of  chronic liver disease in Western 
countries[1]. The prevalence of  NAFLD is increasing and 
varies significantly with ethnicity, ranging from 24% in 
blacks to 33% in whites and 45% in Hispanics according 
to a recent study from the United States[2]. The mortality 
rate of  NAFLD patients in the community was found to 
be higher than that of  the general population in both the 
US and Sweden[3]. During an average 7.6 years of  follow-
up, 13% of  the patients died, mainly from malignancy, 
coronary heart disease (CHD) and liver-related mortal-
ity[4]. Another study revealed that the survival of  patients 
with nonalcoholic steatohepatitis (NASH) was reduced 
and that these patients died significantly more often 
from CHD and liver-related causes[3]. Patients with more 
advanced liver fibrosis tend to have more liver complica-
tions than those without liver fibrosis[4]. Liver biopsy is 
considered the gold standard for the diagnosis and as-
sessment of  fibrosis severity but has several limitations, 
such as sampling variability, invasiveness and expense[5]. 
Patients with NASH can have a significant progression 
of  fibrosis within a few years[6-8]. Recently, a simple, 
noninvasive tool used for liver fibrosis assessment has 
been developed[9]. This new scoring system, the NAFLD 
fibrosis score (NFS), is a composite score of  age, hyper-
glycemia, body mass index, platelet count, albumin, and 
aspartate aminotransferase and alanine aminotransferase 
(AST/ALT) ratio[9] and was found to independently iden-
tify NAFLD patients with and without advanced fibrosis 
at initial NAFLD diagnosis. Another clinical score com-
posed of  body mass index (BMI) ≥ 28 kg/m2, AST/
ALT ratio ≥ 0.8 and diabetes mellitus (the BARD score) 
has also been used to predict an increased chance of  
liver fibrosis[10]. However, the BARD score does not have 
the capacity to differentiate the severity of  liver fibrosis 
among patients with a higher BMI or a higher ratio of  
AST/ALT, whereas the NFS takes into consideration the 
different ranges of  BMI or AST/ALT ratios[9]. A study 
from Japan validated the NFS and found it to have an 
acceptable sensitivity, specificity, and positive and nega-
tive predictive values for advanced liver fibrosis of  100%, 
83%, 63%, and 100%, respectively[11]. A longitudinal 
study of  103 NAFLD patients showed that the fibrosis 
stage progressed in 37%, remained stable in 34% and re-
gressed in 29% of  patients with a mean interval between 
liver biopsies of  approximately 3 years[12]. The rate of  
fibrosis change ranged from -2.1 to 1.7 stages per year. 
The prognostic predictors for a higher rate of  liver fibro-
sis were diabetes, a low initial fibrosis stage and a higher 
body mass index. In the current study, we aimed to de-
termine whether the severity of  liver fibrosis estimated 
by the NFS can predict a higher risk of  overall mortality, 
cardiac complications, and/or liver complications among 
patients with NAFLD. Additionally, we aimed to deter-
mine the annual rate of  the NFS change from the base-
line to the end of  the follow-up among NAFLD patients. 
MATERIALS AND METHODS
Study subjects
In this a historical cohort study, patients residing in Ol-
msted County, Rochester, Minnesota, United States who 
had been diagnosed with NAFLD-fatty liver (HICDA 
Code 05710420), fatty liver hypertrophy (HICDA Code 
05710421), fatty liver cirrhosis (HICDA Code 05710422), 
fatty liver steatohepatitis (HICDA Code 05710423) or 
NASH (HICDA Code 05710431), or fatty liver ste-
atohepatitis (HICDA Code 05710-42-43) or steatosis 
(HICDA Code 02790-44-1) between January 1, 1980 and 
January 1, 2000 were drawn from the Rochester Epidemi-
ology Project (REP) master diagnostic index. The REP 
index is a unique database system of  medical diagnoses 
of  the population living in Olmsted County, Minne-
sota[13]. Although fatty liver was recognized prior to 1980, 
this liver condition was better characterized in 1980[14]; 
therefore, we chose to identify patients after this date. 
Inclusion criteria
From the 479 patients with NAFLD assessed, 302 pa-
tients (63%) greater than 18 years old were included. All 
of  these patients were followed, and their medical charts 
were reviewed, until August 31, 2009 or the date when 
the first primary endpoint occurred. By using a standard-
ized case record form, we recorded a detailed history and 
physical examination and use of  statins and metformin 
during the follow-up period.
Exclusion criteria 
We excluded NAFLD patients who lacked the data 
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needed for the NFS calculation, patients with pre-existing 
poor outcomes including overt CHD or overt liver com-
plications at the time of  NAFLD diagnosis and patients 
with duration of  follow-up of  less than 5 years. One 
hundred seventy-seven NAFLD patients were excluded 
due to missing the data needed for the NFS calculation 
(n = 95), overt CHD confirmed at baseline (n = 63), liver 
cirrhosis with complications confirmed at baseline (n = 
11) and duration of  follow-up of  less than 5 years (n = 8). 
Definitions
The diagnosis of  NAFLD was based on a liver biopsy 
showing steatosis in at least 5% of  hepatocytes or fatty 
infiltration of  the liver confirmed by imaging study (ul-
trasound, computed tomography, or magnetic resonance 
imaging) and the exclusion of  liver disease of  other eti-
ologies, including alcohol-induced liver disease (history 
of  excessive alcohol consumption greater than 20 gm/d), 
drug-induced liver disease, autoimmune or viral hepatitis 
and cholestatic or metabolic/genetic liver disease[1]. Cir-
rhosis was defined based on the pathological term for the 
chronic liver diseases[15]. In our study, 85% of  patients 
(n = 256) were diagnosed by liver imaging. Liver biopsy 
was performed in 46 patients (15% of  302 patients). The 
staging of  fibrosis was divided into fibrosis stage 0 to 
stage 4 using the Brunt criteria[16]. The NAFLD patients 
with a histological liver fibrosis stage of  1-2 were classi-
fied as “mild liver fibrosis,” and those with a histological 
fibrosis stage of  3-4 were classified as “advanced liver 
fibrosis”[16]. 
The primary endpoints were all-cause mortality, cardiac 
complications, and/or liver complications. Cardiac com-
plications included new-onset CHD events as recorded in 
the medical records, defined as congestive heart failure, 
unstable angina, myocardial infarction, flow-limiting ste-
nosis from angiography or angina requiring revasculariza-
tion during the follow-up period and need for hospital-
ization[17]. Liver complications were diagnosed by clinical 
signs and symptoms[18], including the presence of  ascites, 
variceal bleeding, a severe grade of  hepatic encephalopa-
thy, liver failure or hepatocellular carcinoma, that oc-
curred during the follow-up and required hospitalization 
with or without death[19]. All causes of  death listed on 
the death certificates or pathological findings (underly-
ing, intermediate, immediate and other major conditions) 
were recorded using the 10th revision of  the International 
Classification of  Diseases (ICD-10). The presence of  
metabolic syndrome (MetS) was defined by using the 
2001 National Cholesterol Education Program Adult 
Treatment Panel Ⅲ (NCEP-ATPⅢ) criteria and the new 
definition, which requires the presence of  at least three 
of  the five features[20,21]. The NFS is composed of  6 vari-
ables, including age, hyperglycemia, BMI, platelet count, 
albumin, and AST/ALT ratio as independent indicators 
of  advanced liver fibrosis[9]. NAFLD fibrosis score = 
-1.675 + 0.037 × age (year) + 0.094 × BMI (kg/m2) + 1.13 
× IFG/diabetes (yes = 1, no = 0) + 0.99 × AST/ALT 
ratio - 0.013 × platelet count (×109/L) - 0.66 × albumin 
(g/dL)[9].
In this study, the NFS was used to classify advanced 
liver fibrosis into 2 categories[9]. NAFLD patients with a 
score less than -1.5 were classified as “low probability of  
advanced liver fibrosis,” and those patients with a score 
of  at least -1.5 were classified as “intermediate or high 
probability of  advanced liver fibrosis”[9]. Because the 
information required for determination of  the NFS was 
not always available on the same day, the scores were cal-
culated at the time of  NAFLD diagnosis using data from 
the medical records from visits within 3 mo of  the “true” 
NAFLD diagnosis date and the last follow-up date. If  
more than one assessment for a given variable was avail-
able in the medical records during this time period, the 
value closest to the “true” follow-up date was used for 
the NFS calculation[9]. According to the 3 subgroups of  
low, intermediate and high probability of  fibrosis, we 
used parameters of  NFS < -1.5 for low, NFS ≥ -1.5 to 
NFS < 0.67 for intermediate and NFS ≥ 0.67 for high 
probability of  fibrosis at baseline. 
At the end of  the follow-up period, we classified the 
patients into 3 subgroups according to the progression 
pattern of  the liver fibrosis by comparing the NFS at 
baseline to the end of  follow-up. The first group had 
stable fibrosis, defined as stability of  the NFS during the 
follow-up. The second group had regression of  fibrosis, 
defined as a reduction of  the NFS to a milder stage of  
fibrosis during the follow-up. Lastly, the third group had 
fibrosis progression, defined as an increase of  the NFS 
to a more advanced stage during the follow-up.
Sample-size/statistical power considerations
We assumed that the overall mortality rate in NAFLD 
would be 12%, with liver-related complications being 
observed in at least 3% and cardiac complications in 
11% of  patients based on results from a previous study[4]. 
We anticipated that at least 150 patients, or 50% of  the 
total cohort, would be classified as “low probability of  
advanced liver fibrosis” using the NFS, and at least 150 
would be classified as “intermediate or high probability 
of  advanced liver fibrosis”[12]. However, a portion of  
patients were expected to develop new CHD events, 
liver complications and death. We anticipated that 15% 
of  patients would be identified as having experienced 
a primary endpoint. We assumed that, at most, 10% of  
patients with a low probability of  advanced liver fibrosis 
would experience events within 5 years and at least 20% 
of  patients with an intermediate or high probability of  
advanced liver fibrosis would experience events within 5 
years to obtain a statistical power of  at least 82%.
Statistical analysis
Patients were categorized by the NFS into 2 groups of  
probability of  advanced liver fibrosis. Differences be-
tween the primary endpoints of  the two groups of  low 
and high NFS were compared by using the χ 2 test. Dif-
ferences between NAFLD patients with and without 
primary endpoints were tested by independent t tests for 
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continuous variables and were tested by the χ 2 test for 
proportions. Continuous outcomes were presented as 
the mean ± SD, and categorical data were presented as 
numbers (percentage). Logistic regression analysis was 
used to identify the factors significantly associated with 
death among NAFLD patients. Only those variables 
with a P value < 0.1 by univariate analysis were included 
in multivariate analysis. To avoid overestimation of  the 
model, we excluded those variables used as a part of  the 
NFS calculation. We estimated receiver operating char-
acteristics of  related variables for the predicting of  death 
to maximize the area under the curve (AUC). Two-sided 
P values < 0.05 were considered statistically significance. 
The rate of  NFS change in each patient was calculated 
by the difference of  NFS at the end of  follow-up and at 
baseline divided by the duration of  the follow-up time (Δ 
NFS/Δ time). Both phases of  the study used the SPSS 
statistical software package (SPSS Version 15.0.1.1, Win-
dows VISTA, July 3, 2007) for analysis. The study was 
approved by the Institutional Review Board (IRB) of  the 
Mayo Clinic, Rochester, MN, United States, and all partic-
ipants provided permission for their medical information 
to be used for research.
RESULTS
Baseline characteristic data of 302 patients with NAFLD 
This study included three hundred two NAFLD patients 
aged 47 ± 13 year (range 21-86 year), of  which 95% were 
white, and 44% were male. Obesity was present in 73%, 
and a history of  diabetes mellitus type Ⅱ and hyperten-
sion was observed in 16% and 41%, respectively.  Eighty-
five percent of  patients (n = 256) were diagnosed by liver 
imaging. Liver biopsy was performed in 46 patients (15%). 
Mild liver fibrosis (stage F 0-2) was found in 34 patients 
(74%), while advanced fibrosis (stage F 3-4) was found in 
12 patients (26%). NAFLD patients who underwent a liver 
biopsy had a significantly lower diastolic blood pressure, 
a lower BMI and a higher AST level than those without 
a liver biopsy (P < 0.05). The characteristics of  the 302 
patients based on the degree of  advanced liver fibrosis 
estimated by the NFS at baseline are shown in Table 1. A 
low probability of  advanced liver fibrosis (NFS < -1.5) was 
found in 60% of  patients, while an intermediate or high 
probability of  advanced liver fibrosis (NFS ≥ -1.5) was 
found in 40%. The mean ± SD value of  NFS in patients 
with a low probability of  advanced liver fibrosis was -2.6 ± 
0.8 and was lower than in patients with an intermediate or 
high probability of  advanced liver fibrosis (-0.4 ± 0.9,  P < 
0.0001). Patients with a low probability of  advanced liver 
fibrosis had a lower CHD risk at baseline, as estimated by 
the Framingham risk score (FRS) calculation, compared 
to patients with an intermediate or high probability of  ad-
vanced liver fibrosis (14% vs 19%, P = 0.003 ).
Clinical outcomes of long-term follow-up
The mean follow-up of  the total cohort was 11.9 ± 3.9 
years for a total of  3594 person-years. Approximately 
47% of  patients with a low probability of  advanced 
liver fibrosis at baseline progressed to an intermediate or 
high probability of  advanced liver fibrosis at the end of  
follow-up, while 94% of  patients with an intermediate 
Table 1  Demographic data of 302 patients by nonalcoholic fatty liver disease fibrosis score at baseline  n  (%) (mean ± SD)
Variable at baseline    Total Patients with a low probability of
 advanced liver fibrosis
Patients with an intermediate or high
probability of advanced liver fibrosis
P  value
(n  = 302)      (NFS < -1.5) (n  = 181)         (NFS ≥ -1.5) (n  = 121)
Age (yr)   47.3 ± 12.9    42.9 ± 11.1   53.8 ± 12.8 < 0.0001
Sex (% male)    132 (44)   92 (51) 40 (33)   0.002
Race, number (% White)    288 (95) 170 (94) 119 (97.5)   0.150
History of diabetes      48 (16)     5 (2.8)   43 (35.5) < 0.0001
History of hypertension    125 (41)   55 (30.4) 70 (58) < 0.0001
BMI (kg/m2)   33.6 ± 6.2  32.0 ± 5.2 36.0 ± 6.9 < 0.0001
Presence of obesity  (BMI > 30 kg/m2)    221 (73) 121 (67) 100 (82.6)   0.002
Systolic blood pressure (mmHg)    136 ± 18  133 ± 17 139 ± 18   0.003
Diastolic blood pressure (mmHg)      83 ± 9  84 ± 8 81 ± 9   0.010
Cholesterol (mg/dL)    214 ± 48  215 ± 46 214 ± 50   0.780
Triglycerides (mg/dL)    221 ± 167    208 ± 123   242 ± 218   0.150
Glucose (mg/dL)    115 ± 41  103 ± 25 132 ± 54 < 0.0001
AST (U/L)   41.4 ± 21.9    40.8 ± 21.8   42.2 ± 28.9   0.620
ALT (U/L)   61.5 ± 43.3 69.7 ± 46   49.4 ± 35.7 < 0.0001
AST/ALT ratio     0.8 ± 0.4    0.7 ± 0.3   1.0 ± 0.6 < 0.0001
GGT (U/L) 131.9 ± 39.8  129.9 ± 32.9 134.2 ± 46.7   0.560
Platelets (× 109/L)    240 ± 62  259 ± 60 212 ± 53 < 0.0001
Albumin (g/dL)     4.3 ± 0.4    4.4 ± 0.3   4.1 ± 0.3 < 0.0001
Alkaline phosphatase (U/L)    196 ± 88  186 ± 68   211 ± 111   0.030
Framingham Risk Score     8.4 ± 6.2    6.9 ± 6.4 10.5 ± 5.2 < 0.0001
Calculated CHD risk (%)   16.2 ± 14.6    14.1 ± 13.8   19.3 ± 15.2   0.003
NFS    -1.7 ± 1.4   -2.6 ± 0.8  -0.4 ± 0.9 < 0.0001
NAFLD: Nonalcoholic fatty liver disease; BMI: Body mass index; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Glutamyltrans-
ferase; CHD: Coronary heart disease; NFS: NAFLD fibrosis score.
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or high probability of  advanced liver fibrosis remained 
in the same group. At the end of  the follow-up, patients 
with an intermediate or high probability of  advanced 
liver fibrosis had a significantly higher BMI, more fre-
quent diabetes, and more frequent histories of  hypothy-
roidism, cholecystectomy and obstructive sleep apnea. 
Furthermore, the patients with an intermediate or high 
probability of  advanced liver fibrosis were more likely to 
use metformin, glitazones and aspirin compared to those 
with a low probability of  advanced liver fibrosis (P < 0.05). 
A history of  diabetes at baseline was found in 16%, 
while the proportion of  patients with NAFLD who de-
veloped impaired fasting glycemia or diabetes during the 
follow-up was 89 patients (29%) with an average interval 
of  6.3 ± 4.2 year (range 0.2-17.2) from the diagnosis of  
NAFLD. Patients who developed impaired fasting glyce-
mia or diabetes during the follow-up were more frequent 
male, had less hypertension, and had a lower NAFLD 
Fibrosis Score at baseline compared to those with diabe-
tes at baseline (P < 0.05). The primary endpoints of  both 
groups were not significantly different.
Patients with an intermediate or high probability of  
advanced liver fibrosis had a significantly higher glucose 
and a higher AST/ALT ratio at the end of  follow-up 
compared to those with a low probability of  advanced 
liver fibrosis. Hematocrit, platelet count, AST, ALT, al-
bumin, cholesterol and low-density lipoprotein (LDL)-
cholesterol level were significantly lower in patients with 
an intermediate or high probability of  advanced liver 
fibrosis compared to those with a low probability of  
advanced liver fibrosis (Table 2). At the end of  follow-
up, 55 patients developed primary endpoints, including 
death or the presence of  CHD or liver complications. 
Thirty of  these patients had new-onset CHD, whereas 8 
of  30 patients (27%) died from CHD-related complica-
tions during the follow-up period (Table 2). Patients with 
new CHD events (n = 30) were significantly older and 
had a higher systolic blood pressure (SBP), FRS at base-
line, calculated % CHD risk at baseline, and NFS at the 
end of  follow-up and exhibited a lower ALT than those 
patients without new CHD events (n = 272) (P < 0.05). 
In addition, the NFS at baseline was similar in patients 
with and without new CHD events (-1.2 ± 1.6 vs -1.8 ± 
1.4, P = 0.07). Liver complications occurred in 6 patients, 
5 of  whom (83%) died during the follow-up. The liver 
complications included massive ascites requiring abdomi-
Table 2  Clinical parameters, laboratory features and clinical outcomes at the end of follow-up by nonalcoholic fatty liver disease 
fibrosis score at baseline  n  (%) (mean ± SD)
Variable at the end of follow-up Patients with a low probability of
 advanced liver fibrosis 
Patients with an intermediate or high 
probability of advanced liver fibrosis
P  value
(NFS < -1.5) (n  = 181) (NFS > -1.5) (n  = 121)
Clinical findings
BMI (kg/m2) 32.9 ± 6.6  34.9 ± 7.6     0.02
Obesity (BMI > 30 kg/m2)    119 (65.8)      91 (75.2)     0.08
NFS -1.4 ± 1.3    0.4 ± 1.4 < 0.0001
NFS of intermediate or high probability of advanced liver fibro-
sis
  85 (47) 114 (94) < 0.0001
History of diabetes      54 (29.8)      83 (68.6) < 0.0001
Use of metformin      32 (17.7)      48 (39.7) < 0.0001
Use of glitazones    10 (5.5)      19 (15.7)     0.003
Use of aspirin   84 (46)   83 (69)     0.0001
History of hypothyroidism      19 (10.5)      31 (25.6)     0.0005
History of cholecystectomy   27 (15)      33 (27.3)     0.008
History of obstructive sleep apnea      33 (18.2)      34 (28.1)     0.04
Laboratory findings
   AST (U/L)   38.9 ± 30.6    33.2 ± 17.8     0.04
   ALT (U/L)   53.9 ± 49.7 38.9 ± 21     0.0004
   AST/ALT ratio   0.8 ± 0.5    1.0 ± 0.8     0.03
   Hematocrit (%) 40.4 ± 4.4  38.6 ± 5.3     0.003
   Platelets (× 109/L) 259 ± 67  217 ± 74 < 0.0001
   Albumin (g/dL)   4.1 ± 0.4    3.9 ± 0.6 < 0.0001
   Cholesterol (mg/dL) 193 ± 40  178 ± 43     0.005
   LDL-cholesterol (mg/dL) 109 ± 34    92 ± 30 < 0.0001
   Glucose (mg/dL) 119 ± 42  131 ± 42     0.02
Clinical outcomes at the end of follow-up 
   Lost to follow up   27 (15)   8 (7)
   Alive with continued follow-up 131 (72)   81 (67)
   Presence of primary endpoints   23 (13)   32 (26)     0.002
   All-cause death    12 (6.6)      27 (22.3) < 0.0001
   New events of coronary heart disease    15 (8.3)      15 (12.4)     0.24
   Liver complications      1 (0.6)      5 (4.1)     0.03
NAFLD: Nonalcoholic fatty liver disease; BMI: Body mass index; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; NFS: NAFLD fibrosis 
score; LDL: Low-density lipoprotein.
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nal paracentesis (n = 3), hepatopulmonary syndrome and 
hepatocellular carcinoma (n = 1 each).
A total of  39/302 (13%) patients died during the 
follow-up period. The leading causes of  death were non-
hepatic malignancy (n = 13/39; 33.3%), CHD (n = 8/39; 
20.5%), and liver related mortality (n = 5/39; 12.8%). 
The other 13 patients (33.3%) died from various causes 
(Table 3). The primary types of  cancers were gastric can-
cer (n = 2), colon cancer (n = 2), pancreatic cancer (n = 2), 
breast cancer (n = 2), leiomyosarcoma of  uterus (n = 1), 
diffuse B cell lymphoma (n = 1), endometrial cancer (n = 
1), lung cancer (n = 1) and unknown primary cancer with 
liver metastasis (n = 1). Additionally, our study showed 
a significant, graded relationship between the NAFLD 
fibrosis score, classified into 3 subgroups (low, intermedi-
ate and high probability of  liver fibrosis), and the occur-
rence of  primary endpoints, as shown in Table 4.
Predicting mortality
Patients who died (n = 39) were significantly older with 
more frequent diabetes and had a higher SBP, NFS at 
baseline, FRS, glucose, and a lower diastolic blood pres-
sure, ALT and albumin (Table 5). Moreover, they had 
greater NFS changes per year than those who survived (n 
= 263, P <0.05).  Three models of  multivariate analysis 
were used to identify the best fit model for predictors of  
death and are illustrated in Table 6. In model 1, we added 
9 variables, including gender, systolic blood pressure, 
diastolic blood pressure, NFS at baseline, use of  metfor-
min, use of  simvastatin, use of  aspirin, presence of  new-
onset CHD and new-onset liver complications, without 
interaction among these variables. Model 2 included 10 
variables, gender, systolic blood pressure, diastolic blood 
pressure, NFS at baseline, NFS changes per year, use of  
metformin, use of  simvastatin, use of  aspirin, presence 
of  new-onset of  CHD and new-onset of  liver complica-
tions without interaction among these variables. Finally, 
model 3 added the interaction between NFS at baseline 
and NAFLD NFS changes per year with the use of  as-
pirin, metformin, and simvastatin into model 2. We did 
not add the FRS into these models due to the repetition 
of  several variables in the NFS and the FRS. Model 3 
was the best fit model, which found that a higher NFS at 
baseline and more frequent new-onset CHD were signifi-
cantly predictive of  death (OR = 2.6 and 9.2, respective-
ly; P < 0.0001). The use of  metformin or simvastatin for 
at least 3 mo during the follow-up were associated with 
fewer deaths in patients with NAFLD (OR = 0.2 and 0.03, 
respectively; P < 0.05). 
Table 7 showed the results of  the comparison of  
NAFLD patients with and without death after excluding 
those with established type 2 diabetes at baseline (n = 
254). After excluding patients with established type 2 dia-
betes at baseline, we found that a higher NFS at baseline 
and higher alkaline phosphatase remained significantly 
predictive of  death (OR = 1.9 and 1.006; P <0.0001 and 
0.012, respectively) as shown in Table 8. Additionally, Ta-
ble 9 showed that non-diabetic patients with intermediate 
or high probability of  liver fibrosis had a significantly 
higher rate of  primary end point and all-cause death than 
those patients with low probability of  liver fibrosis.
Using the ROC curves to predict death, we found that 
a baseline NFS of  -0.9 was the best cutoff  value with a 
sensitivity of  62%, specificity of  76%, positive predictive 
value of  28%, negative predictive value of  93% and AUC 
of  0.7 (Figure 1). 
The median rate of  annual NFS change for all pa-
tients was 0.1 (IQR of  0.02, 0.13). The rate of  annual 
NFS change in patients with an intermediate or high 
probability of  advanced liver fibrosis was significantly 
lower than in patients with a low probability of  advanced 
liver fibrosis (0.06 vs 0.09, P = 0.004). The annual NFS 
change in patients who died was significantly higher than 
those in patients who survived (0.14 vs 0.07, P = 0.03). At 
the end of  the follow-up, we classified the patients into 
3 subgroups according to the progression pattern of  the 
Table 3  Causes of mortality in 39 patients with nonalcoholic 
fatty liver disease
Causes of death All causes mortality 
n  (% of death)
All causes mortality 
(% of 302 patients)
Non-liver cancer 13 (33.3)   4.3%
Coronary heart disease   8 (20.5)   2.6%
Liver-related mortality (inclu-
ding hepatocellular carcinoma)
  5 (12.8)   1.7%
Infection (including sepsis)   4 (10.3)   1.3%
Stroke 3 (7.7)   1.0%
Cardiac arrhythmia 2 (5.1)   0.7%
COPD and/or respiratory 
failure
2 (5.1)   0.7%
Other causes of death (GI 
bleeding, renal failure)
2 (5.1)   0.7%
Total 39 (100) 12.9%
COPD: Chronic obstructive lung disease; GI: Gastrointestinal. 
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Figure 1  Presence of death estimated by the nonalcoholic fatty liver dis-
ease fibrosis score at baseline. Using the receiver operating characteristics 
curve, the nonalcoholic fatty liver disease fibrosis score at baseline of -0.9 was 
the best cutoff value for predicting death based on a sensitivity of 62%, specific-
ity of 76%, positive predictive value of 28%, negative predictive value of 93% 
and area under the curve of 0.7.
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liver fibrosis by comparing the NFS at baseline to that at 
the end of  follow-up. Most patients were in the stable-
fibrosis (60%) and progressive-fibrosis (37%) groups, 
whereas only 3% were in the regressive-fibrosis group. 
The annual NFS change in the progressive-fibrosis group 
and the stable-disease group was 0.20 ± 0.02 and 0.05 ± 
0.08, respectively (P = not significant).
DISCUSSION
In the current study, we found that a higher NFS at 
baseline and the presence of  new-onset CHD were sig-
nificantly predictive of  death. The use of  noninvasive 
methods to predict poor clinical outcomes in NAFLD 
patients during follow-up is urgently needed. Studies 
of  noninvasive markers used to identify steatohepatitis 
patients from NAFLD patients require validation before 
being widely used, as previously suggested[22]. Although 
liver biopsy is the currently recommended practice for 
identifying liver fibrosis, in NAFLD patients with risk 
factors that include older age, diabetes, severe obesity 
and metabolic syndrome, serial liver biopsies are invasive 
and are not applicable in clinical practice. Recently, Rafiq 
et al[22] showed that at least 3 risk factors, including type 
Table 4  Association between the primary endpoint and the grading of the nonalcoholic fatty liver disease fibrosis score, classified 
into 3 subgroups (n  = 302)  n  (%)
Grading of the NAFLD fibrosis score 
(n  =  302)
Low prob. of advanced liver 
fibrosis (n  = 181)
Intermediate prob. of advanced liver 
fibrosis (n  = 108)
High prob. of advanced 
liver fibrosis (n  = 13)
P  value
Presence of primary endpoint (n = 55, 18.2%)            23/181 (12.7)            24/108 (22.2)            8/13 (61.5) < 0.0001
All-cause death  (n = 39, 12.9%)            12/181 (6.6)            21/108 (19.4)            6/13 (46.2) < 0.0001
NAFLD: Nonalcoholic fatty liver disease.
Table 5  Comparison of nonalcoholic fatty liver disease patients alive vs  deceased  n  (%) (mean ± SD)
Variables NAFLD patients alive (n  = 263) NAFLD patients deceased (n  = 39) P  value
At baseline
   Age (yr)   45.2 ± 11.5   61.1 ± 13.8 < 0.0001
   Sex (% male)    120 (45.6)      12 (30.8)     0.08
   History of diabetes      37 (14.1)      11 (28.2)     0.02
   Systolic blood pressure (mmHg)    134 ± 17    143 ± 21     0.02
   Diastolic blood pressure (mmHg)      83 ± 8      79 ± 10     0.03
   Glucose (mg/dL)    112 ± 38.6 132.7 ± 54.3     0.03
   AST (U/L)   42.2 ± 25.5   35.5 ± 20.0     0.06
   ALT (U/L)   64.2 ± 44.6   43.6 ± 27.4     0.000
   AST/ALT ratio     0.8 ± 0.4     1.0 ± 0.7     0.06
   Albumin (g/dL)     4.3 ± 0.3     4.0 ± 0.4 < 0.0001
   FRS     7.9 ± 6.2   11.4 ± 5.2     0.000
   Calculated CHD risk (%)   15.3 ± 14.0   22.2 ± 17.1     0.02
   NFS    -1.9 ± 1.3    -0.8 ± 1.7     0.0004
   NFS of intermediate or high probability of advanced liver fibrosis (%)      94 (35.7)      27 (69.2) < 0.0001
   Presence of histologically advanced liver fibrosis  7/35 (20.0) 5/11 (45.5)     0.09
During the follow-up period      77 (29.3)        3 (7.7)     0.004
   Use of metformin 
   Use of aspirin    151 (57.4)      16 (41.0)     0.05
   Use of simvastatin    107 (40.7)         3 (7.9) < 0.0001
   New events of coronary heart disease      16 (6.1)      14 (35.9) < 0.0001
   Liver complications        1 (0.4)        5 (12.8) < 0.0001
At the end of follow-up
   BMI (kg/m2)   33.9 ± 6.9   31.8 ± 8.2     0.1
   Hematocrit (%)   40.4 ± 4.1   34.5 ± 6.3 < 0.0001
   Glucose (mg/dL) 122.0 ± 38.6 139.0 ± 62.3     0.12
   AST/ALT ratio     0.9 ± 0.5     1.3 ± 1.0     0.01
   Albumin (g/dL)     4.1 ± 0.3     3.3 ± 0.7 < 0.0001
   Creatinine (mg/dL)     1.0 ± 0.5     1.7 ± 1.3     0.004
   NFS    -0.9 ± 1.4     0.7 ± 2.3 < 0.0001
   NFS change per year (Median; IQR)   0.07 (0.02, 0.12)   0.14 (0.01, 0.31)     0.03
   NFS of intermediate to high probability of advanced liver fibrosis (%)    168 (63.9)      31 (79.5)     0.05
To avoid overestimation of the model, we excluded those variables used as a part of NAFLD fibrosis score calculation (age, history of diabetes, aspartate 
aminotransferase/alanine aminotransferase ratio, platelet count, albumin, body mass index and Framingham risk score). NAFLD: Nonalcoholic fatty liver 
disease; BMI: Body mass index; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; FRS: Framingham risk score; CHD: Coronary heart dis-
ease; NFS: NAFLD fibrosis score.
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2 diabetes, older age and low albumin level, were predic-
tors of  mortality and liver-related mortality. Most of  
these risk factors are components of  the NFS[9]. Thus, 
a benefit of  the current study is an extension of  the 
clinical use of  the NFS system for predicting death in 
patients with NAFLD.
Our results show that the annual NFS change in pa-
tients who died was two times higher than in survivors 
during the follow-up. Thus, it would be valuable to calcu-
late NFS in newly diagnosed patients. 
The annual rate of  NFS change in the progressive-fi-
brosis group was approximately 4 times higher than that 
in the stable-disease group. Therefore, the median value 
of  the annual rate of  NFS change might be used as a 
surrogate marker for progression of  liver fibrosis, but 
this measure requires further study to validate its benefit.
The long-term outcomes of  patients with NAFLD 
are not uniform across the spectrum of  the disease[3,22,23]. 
Poor outcomes are more frequent in patients with NASH, 
which was confirmed by our results, which showed 
patients with an intermediate or high probability of  ad-
vanced liver fibrosis had an increased frequency of  pri-
mary endpoints, all-cause deaths, and liver complications 
compared to those with a low probability of  advanced 
liver fibrosis.
Several previous studies have demonstrated a higher 
mortality rate (30%-45%) than observed in the current 
study (13%). This difference may be at least partly ex-
plained by a difference in patient selection. For instance, 
the prevalence of  diabetes or impaired glucose tolerance, 
a well-known risk factor for increased mortality, was 
three times higher in a Swedish study than in the current 
study (53% vs 16%)[3]. In addition, previous studies did 
not exclude patients with known CHD or known liver 
complications at baseline[3,22,23].
The use of  metformin or simvastatin was found to 
be a protective factor against death in the present study. 
This finding is in line with a study by Ekstedt et al[24], 
who showed a significant reduction in liver steatosis in 
NAFLD patients on statins vs those not on statins. A 
recent study found diabetes mellitus to be one of  the 
important predictors for developing moderate to severe 
liver fibrosis[25], and treatment with metformin improved 
liver histology and ALT levels in one-third of  patients 
with NASH[26]. Two other studies suggested that metfor-
min improved only the insulin sensitivity but did not im-
prove liver histology in NASH patients[26,27]. Limited data 
exist concerning the efficacy of  metformin in patients 
with NAFLD, and the result of  the current study does 
not necessarily imply causality. Our results show that the 
use of  simvastatin seems to improve the prognosis in pa-
tients with NAFLD. This improvement may relate to the 
effect on prevention of  new-onset CHD, which account-
ed for 20% of  deaths in our study. Recent data showed 
that the statins are safe and well-tolerated in patients with 
NAFLD[28-32]. Moreover, the use of  statins was associ-
ated with a reduction of  hepatic steatosis in NAFLD pa-
tients[24,32,33]. No study has assessed the efficacy of  statins 
to reduce CHD mortality in NAFLD patients, although 
the benefits are well-recognized for both the primary 
and secondary prevention of  CHD and the reduction 
of  overall mortality in the general population[34,35]. Thus, 
the benefit of  statins for CHD prevention in NAFLD 
patients with dyslipidemia and/or a high calculated risk 
of  coronary heart disease by the FRS should be consid-
ered[36,37].
The main strengths of  our study are the inclusion of  
NAFLD patients from the community along with the 
long-term follow-up. All patients had complete data for 
calculation of  the NFS at the time of  NAFLD diagnosis 
and at the end of  the follow-up. The exclusion of  known 
CHD or liver cirrhosis with complications at baseline is 
important to reduce the overestimation of  the incidence 
of  primary endpoints or mortality rate during the follow-
up period.
Our study has several limitations. First, only 6.6% 
of  the patients with a low probability of  advanced liver 
fibrosis died, which was less than expected (10%) by a 
sample size calculation and may affect the power of  the 
study. Second, most of  our patients in Olmsted County 
are white, and recent data showed that non-Caucasian 
Table 6  Multivariate logistic regression model showing OR 
(95%CI) for predictors for death in 302 patients with non-
alcoholic fatty liver disease
Multivariate analysis P  value   OR   95%CI
Model 1
   Presence of new-onset CHD < 0.0001    9.0     2.9-28.4
   NFS at baseline < 0.0001    1.9     1.4-2.6
   Use of metformin     0.02    0.2   0.04-0.8
   Use of simvastatin                0.001    0.05   0.01-0.3
Model 2 
   NFS changes per year     0.04  14.9     1.1-206.4
   Presence of new onset of CHD     0.001    8.0     2.4-26.1
   NFS at baseline < 0.0001    2.1     1.5-2.9
   Use of metformin     0.02    0.2   0.04-0.7
   Use of simvastatin                0.001    0.06   0.01-0.3
Model 3 
   Presence of new onset of CHD < 0.0001    9.2     2.6-32.2
   NFS at baseline < 0.0001    2.6     1.7-3.9
   Use of metformin     0.03    0.2   0.04-0.8
   Use of simvastatin       0.001    0.03 0.003-0.2
   Interaction between NFS     0.004    0.06 0.008-0.4
   at baseline and NFS
   change per year
   NFS changes per year     0.6    2.2 0.07-67.8
Model 1 without interaction among 9 included variables: gender, systolic 
blood pressure, diastolic blood pressure, nonalcoholic fatty liver disease 
(NAFLD) fibrosis score at baseline, use of metformin, use of simvastatin, 
use of aspirin, presence of new-onset of coronary heart disease (CHD) and 
new onset of liver complications; Model 2 without interaction among 10 
included variables: gender, systolic blood pressure, diastolic blood pres-
sure, NAFLD fibrosis score (NFS) at baseline, NFS changes per year, use of 
metformin, use of simvastatin, use of aspirin, presence of new-onset coro-
nary heart disease (CHD) and new onset of liver complications; Model 3 
added variables of interaction between NFS at baseline and NFS changes 
per year, interaction among use of aspirin, metformin, aspirin and simvas-
tatin into model 2. 
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race was an important predictor of  decreased survival[22]. 
With the relatively small sample size and the represented 
local population in the United States, our results are not 
necessarily applicable in other ethnic groups.
The current study is important because we extended 
the clinical use of  the NFS system for predicting death 
or liver complications in NAFLD patients. A higher NFS 
at baseline and the presence of  new-onset CHD can 
be used as prognostic predictors for mortality and liver 
complications among NAFLD patients. Further research 
is needed to validate the benefit of  the NFS for predict-
ing death or liver complications in NAFLD patients with 
other ethnic groups. The NFS is simpler and less invasive 
than liver biopsy for the initial evaluation of  the degree 
of  liver fibrosis in patients with NAFLD. The NFS 
should be calculated for all patients with NAFLD at ini-
tial consultation to estimate the probability of  advanced 
liver fibrosis. 
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Table 7  Comparison of nonalcoholic fatty liver disease patients with and without death after excluding those with established type 
2 diabetes at baseline (n = 254)  n  (%) (mean ± SD)
Variables NAFLD patients without death (n  = 226) NAFLD patients with death (n  = 28) P  value
Age (yr)   44.5 ± 11.5   59.2 ± 14.3 < 0.0001
Sex (% male) 113 (50)     10 (35.7)     0.11
History of hypercholesterolemia   56 (24.8)       9 (32.1) < 0.0001
Obesity 164 (72.6)     22 (78.6)     0.34
BMI (kg/m2) 33.5 ± 6.2 35.0 ± 6.6     0.25
Platelet count (× 109/mm3)  241 ± 58 242 ± 87     0.98
Glucose (mg/dL) 215.7 ± 46.6 215.7 ± 46.6
Cholesterol (mg/dL)  215 ± 48  219 ± 56     0.72
HDL-cholesterol (mg/dL)    42 ± 12    43 ± 20     0.76
AST (U/L)   42.0 ± 23.0    39.7 ± 21.0     0.62
ALT (U/L)   65.7 ± 45.0    50 ± 29     0.02
AST/ALT ratio   0.76 ± 0.38   0.93 ± 0.57     0.14
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Albumin (g/dL)   4.3 ± 0.3   4.2 ± 0.4 < 0.0001
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Calculated CHD risk (%)   15.3 ± 14.4   22.0 ± 18.8     0.076
NFS  -2.11 ± 1.15  -1.09 ± 1.61     0.003
NFS of intermediate or high probability of advanced liver 
fibrosis (%)
  59 (26.1)     19 (67.9) < 0.0001
B. During the follow-up periods
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Use of simvastatin   90 (39.8)             3 (10.7) < 0.0001
NFS change per year (median; IQR)   0.08 ± 0.08   0.12 ± 0.36     0.61
In order to avoid overestimation of the model, we excluded those variables used as a part of nonalcoholic fatty liver disease fibrosis score calculation (age, 
history of diabetes, aspartate aminotransferase/alanine aminotransferase ratio, platelet counts, albumin, body mass index and Framingham risk score). 
NAFLD: Nonalcoholic fatty liver disease; BMI: Body mass index; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; FRS: Framingham risk 
score; CHD: Coronary heart disease; NFS: NAFLD fibrosis score; ALP: Alkaline phosphatase; GGT: Glutamyltransferase; HDL: High-density lipoprotein.
Table 8  Multivariate logistic regression model showing OR 
(95%CI) of predictors for death in 254 patients with non-
alcoholic fatty liver disease after excluding those with estab-
lished type 2 diabetes at baseline
Multivariate analysis P  value OR  95%CI
NAFLD fibrosis score at baseline < 0.0001 1.92     1.4-2.7
Alkaline phosphatase    0.012 1.006 1.001-1.010
Model without interaction among 8 included variables; gender, nonalco-
holic fatty liver disease fibrosis score at baseline, use of metformin, use of 
simvastatin, use of aspirin, history of hypercholesterolemia, alanine ami-
notransferase and alkaline phosphatase. NAFLD: Nonalcoholic fatty liver 
disease.
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